GleamWall
中文EN

INBS INTELLIGENT BIO SOLUTIONS INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1725430 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY57.2%
TTM net income YoY-11.4%
TTM EPS YoY74.6%
Revenue 3-yr CAGR27.6%
Net income 3-yr CAGR—

Margins

Gross margin50.9%
Operating margin-272.2%
Net margin-269.3%
FCF margin—
EBITDA margin-246.5%

Returns

ROE-216.1%
ROA-102.3%
ROIC (approx.)-534.9%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets46.0%
Debt / equity0.00x
Current ratio1.98x
Interest coverage-187.68x

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$4.22M$3.05M$3.11M$1.26M$437,146
Cost of revenue$2.17M$1.81M$1.69M$930,204—
Gross profit$2.05M$1.25M$1.43M$326,668—
SG&A expense$10.50M$8.92M$9.26M$8.03M$4.92M
Operating income-$12.61M-$10.68M-$10.28M-$12.60M-$8.34M
Interest expense$10,736$26,339$167,140——
Net income-$12.43M-$10.57M-$10.16M-$10.63M-$8.31M
EBITDA-$11.44M-$9.47M-$9.31M-$11.78M-$8.34M
EPS (basic)-8.44-20.04-6.38-127.00-11.33
EPS (diluted)-8.44-20.04-6.38-127.00-11.33
Weighted avg. shares (diluted)1.47M527,3641.59M83,717733,263
Balance sheet
Cash & equivalents$3.99M$1.02M$6.30M$1.54M$8.24M
Receivables$848,464$594,614$429,704$293,861—
Inventory$418,577$635,215$777,537$979,907—
Current assets$7.10M$4.14M$8.53M$3.86M$10.87M
PP&E, net$294,399$251,325$565,850$690,175$391,408
Intangibles$2.80M$3.79M$4.37M$5.26M—
Total assets$11.94M$8.25M$13.78M$10.35M$12.35M
Current liabilities$4.93M$5.35M$5.45M$5.88M$4.66M
Total liabilities$6.65M$5.44M$5.60M$6.67M$5.81M
Shareholders' equity$5.51M$3.00M$8.33M$3.80M$6.62M
Shares outstanding2.91M732,3273.46M194,200744,496
Cash flow statement
Operating cash flow-$11.93M-$9.68M-$9.57M-$7.38M-$3.36M
Capital expenditure$125,731$231,838$221,426——
Free cash flow-$12.05M-$9.91M-$9.79M——
Investing cash flow-$85,573-$231,838-$221,426-$694,142-$880,221
Financing cash flow$14.98M$4.60M$14.56M$1.44M—
Depreciation & amortization$1.16M$1.21M$974,355$814,481$0
Stock-based compensation$195,208$238,045$230,496$260,000—

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.